X4P-001 and Inlyta Combo Shows Promise Against Kidney Cancer, Trial Indicates
News
A combination of X4P-001 and Inlyta (axitinib) has shown signs of activity against clear cell renal cell carcinoma (ccRCC) in a Phase 1/2 clinical trial. X4 Pharmaceuticals, which developed X4P-001, presented the findings in a poster session at the ... Read more